A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-29 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
The Dexcom CGM is a continuous glucose monitoring system developed by Dexcom, Inc., a company specializing in glucose monitoring technology for individuals with diabetes. Several iterations of the Dexcom CGM wearable device have been released, beginning with the Dexcom Short-Term Sensor (STS), followed by the Dexcom Seven and Dexcom Seven Plus. Later models include the Dexcom G4, Dexcom G5, Dexcom G6, and Dexcom G7. The most recently released model, Stelo by Dexcom, is a more affordable option designed for individuals with type 2 diabetes. Dexcom was founded in 1999 by John Burd and released its first CGM, the Dexcom STS, in 2006 following U.S. Food and Drug Administration (FDA) approval. As of 2025, only the Dexcom G6, Dexcom G7, and Stelo remain available.
A large number of illnesses and diseases are caused by mutations in alleles of the genes that regulate the production of actin or of its associated proteins. The production of actin is also key to the process of infection by some pathogenic microorganisms. Mutations in the different genes that regulate actin production in humans can cause muscular diseases, variations in the size and function of the heart, as well as deafness. The make-up of the cytoskeleton is also related to the pathogenicity of intracellular bacteria and viruses, particularly in the processes related to evading the actions of the immune system.
== Forms of hair removal and methods == Depilation is the removal of the part of the hair above the surface of the skin. The most common form of depilation is shaving or trimming. Another option is the use of chemical depilatories, which work by breaking the disulfide bonds that link the protein chains that give hair its strength. Epilation is the removal of the entire hair, including the part below the skin. Methods include waxing, sugaring, epilators, lasers, threading, intense pulsed light or electrology. Hair is also sometimes removed by plucking with tweezers.
=== Blood pressure control === Modulating and ameliorating diabetic complications may improve the overall quality of life for diabetic patients. For example, a 2008 study concluded that when elevated blood pressure was tightly controlled, diabetic related deaths were reduced by 32% compared to those with less controlled blood pressure.
==== Cinéma-vérité ==== Cinéma vérité (or the closely related direct cinema) was dependent on some technical advances to exist: light, quiet and reliable cameras, and portable sync sound. Cinéma vérité and similar documentary traditions can thus be seen, in a broader perspective, as a reaction against studio-based film production constraints. Shooting on location, with smaller crews, would also happen in the French New Wave, the filmmakers taking advantage of advances in technology allowing smaller, handheld cameras and synchronized sound to film events on location as they unfolded. Although the terms are sometimes used interchangeably, there are important differences between cinéma vérité (Jean Rouch) and the North American "direct cinema", pioneered by, among others, Canadians Michel Brault, Pierre Perrault and Allan King, and Americans Robert Drew, Richard Leacock, Frederick Wiseman and Albert and David Maysles. The directors of the movement take different viewpoints on their degree of involvement with their subjects. Kopple and Pennebaker, for instance, choose non-involvement (or at least no overt involvement), and Perrault, Rouch, Koenig, and Kroitor favor direct involvement or even provocation when they deem it necessary. The films Chronicle of a Summer (Jean Rouch), Dont Look Back (D. A.
Sources: en.wikipedia.org
Balance of terror Balance of threat Mutual assured destruction – a theory in which two or more states are balanced by their ability to effectively completely destroy each other Negarchy Offshore balancing Peace through strength Polarity (international relations) Soft balancing Sphere of influence Superpower Strategic autonomy In history:
2C-B tablets often contain a dose of 5 or 10 mg of the drug. Low doses of 2C-B like 5 to 10 mg orally are said to produce stimulation, entactogen-like effects, and perceptual enhancement, while higher doses like 10 to 20 mg orally are said to produce psychedelic and hallucinogenic effects. 2C-B is frequently used at low doses as a substitute for MDMA. It is often used by people who go to electronic music festivals, also known as raves. The drug is also frequently used at clubs and parties, at home, or in nature. 2C-B is often combined with other drugs, such as MDMA, alcohol, and cannabis. Besides recreational use, 2C-B has been used in psychedelic-assisted psychotherapy at doses of 15 to 30 mg orally.
Lactation suppression Hyperprolactinemia Adjunctive therapy of prolactin-producing pituitary gland tumors (prolactinomas); Monotherapy of Parkinson's disease in the early phase; Combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson's disease; In some countries also: ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, nonpuerperal mastitis and galactorrhea); Treatment of uterine fibroids. Adjunctive therapy of acromegaly: Cabergoline has low efficacy in suppressing growth hormone levels and is highly efficient in suppressing hyperprolactinemia, which is present in 20–30% of acromegaly cases. Growth hormone and prolactin are similar structurally and have similar effects in many target tissues; therefore, targeting prolactin may help symptoms when growth hormone secretion cannot be sufficiently controlled by other methods. Cabergoline is frequently used as a first-line agent in the management of prolactinomas due to its higher affinity for D2 receptor sites, less severe side effects, and more convenient dosing schedule than the older bromocriptine, though in pregnancy bromocriptine is often still chosen since there is less data on safety in pregnancy for cabergoline.
However, as neptunium does in fact occur in nature in trace amounts, as demonstrated when it was found in uranium ore in 1952, it is possible that Hulubei and Cauchois did in fact observe neptunium. Although by 1938 some scientists, including Niels Bohr, were still reluctant to accept that Fermi had actually produced a new element, he was nevertheless awarded the Nobel Prize in Physics in November 1938 "for his demonstrations of the existence of new radioactive elements produced by neutron irradiation, and for his related discovery of nuclear reactions brought about by slow neutrons". A month later, the almost totally unexpected discovery of nuclear fission by Hahn, Meitner, and Otto Frisch put an end to the possibility that Fermi had discovered element 93 because most of the unknown half-lives that had been observed by Fermi's team were rapidly identified as those of fission products. Perhaps the closest of all attempts to produce the missing element 93 was that conducted by the Japanese physicist Yoshio Nishina working with chemist Kenjiro Kimura in 1940, just before the outbreak of the Pacific War in 1941: they bombarded 238U with fast neutrons. However, while slow neutrons tend to induce neutron capture through a (n, γ) reaction, fast neutrons tend to induce a "knock-out" (n, 2n) reaction, where one neutron is added and two more are removed, resulting in the net loss of a neutron.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.